13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults
- 1.1k Downloads
The 13-valent pneumococcal conjugate vaccine (Prevenar 13®, Prevnar 13®) [PCV13] consists of 13 serotype-specific polysaccharides of Streptococcus pneumoniae (pneumococcus), each covalently conjugated to a non-toxic immunogenic carrier protein. PCV13 has a well established immunogenicity and tolerability profile in adults, particularly those ≥50 years of age. Results of CAPiTA, a randomized, double-blind, placebo-controlled trial in >84,000 older adults aged ≥65 years, showed that PCV13 was effective in preventing vaccine-type pneumococcal community-acquired pneumonia (CAP), vaccine-type pneumococcal nonbacteraemic (noninvasive) CAP and vaccine-type invasive pneumococcal disease (IPD). These findings, along with changes in pneumococcal serotype distribution and epidemiology of pneumococcal disease, prompted the US Advisory Committee on Immunization Practices (ACIP) to recommend PCV13 in series with 23-valent pneumococcal polysaccharide vaccine (PPVS23) for all adults aged ≥65 years. PCV13 also has a role in preventing pneumococcal disease (pneumonia and IPD) in younger adults with immunocompromising conditions and potentially in those with other underlying medical conditions that increase the risk of pneumococcal disease.
KeywordsInvasive Pneumococcal Disease Pneumococcal Disease Pneumococcal Pneumonia Inactivate Influenza Vaccine Trivalent Inactivate Influenza Vaccine
During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes based on any comments received were made by the author on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
Greg Plosker is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 2.Centers for Disease Control Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816–9.Google Scholar
- 3.World Health Organization. Pneumococcal disease. http://www.who.int/ith/diseases/pneumococcal/en/. Accessed 7 Apr 2015.
- 17.Leventer-Roberts M, Feldman BS, Brufman I, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015. doi: 10.1093/cid/civ096.
- 21.Pfizer Inc. Prevnar 13 (pneumococcal 13-valent conjugate vaccine): US prescribing information. 2015. http://labeling.pfizer.com/showlabeling.aspx?id=501. Accessed 27 July 2015.
- 22.Prevenar 13 suspension for injection: summary of product characteristics (updated 10 Mar 2015). https://www.medicines.org.uk/emc/history/22689. Accessed 27 July 2015.
- 29.Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–602.CrossRefPubMedGoogle Scholar
- 36.Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.CrossRefPubMedGoogle Scholar
- 58.Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822–5.PubMedGoogle Scholar
- 60.Grijalva CG, Wunderink RG, Williams D, et al. Distribution of pneumococcal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13 [abstract no. ISPPD-0225]. Pneumonia. 2014;3:251.Google Scholar